Tislelizumab for MSI-H or dMMR solid tumors after prior treatment
Treatments studied
Part of Cancer clinical trials.
This trial studies tislelizumab, an immune treatment that blocks PD-1, in people with MSI-H or dMMR solid tumors that cannot be fully removed or have spread, after other treatment has already been tried. It may help your immune system recognize and fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer diagnosis has been confirmed by tissue testing (biopsy or surgery sample)
- Your solid tumor is MSI-H or dMMR (tests from your tumor confirm this)
- Your cancer is locally advanced but not fully removable or has spread (metastatic)
- You’ve had prior treatment for advanced disease
- You can be checked for response: at least one measurable tumor spot on scans
- Your general health is good enough (ECOG 0–1) and your organs function well enough for treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called tislelizumab (a type of immunotherapy) for people with advanced solid tumors that have stopped responding to standard treatments. The drug may help your immune system fight the cancer, but only if your tumor shows a specific genetic marker.
This trial is for people who have completed standard cancer treatments (like surgery, chemo or radiation) and have no visible cancer on scans, but may still have very small amounts of cancer DNA in their blood. The study tests whether the drug tislelizumab can help prevent the cancer from coming back.
This trial tests a drug called tislelizumab for people with advanced lung adenocarcinoma that has spread to the brain but is not causing symptoms. It is for those who have not had prior treatment and whose tumors do not have certain gene changes.
This trial tests whether giving an immunotherapy drug (tislelizumab) together with chemotherapy before and after surgery can improve outcomes for people with a specific type of colorectal cancer (MSI-high). The goal is to see if this treatment helps shrink the tumor and reduces the risk of cancer coming back.
This trial tests the immunotherapy drug tislelizumab for people with a specific type of colorectal or rectal cancer called dMMR. It aims to see if this treatment can shrink tumors or improve outcomes in patients who haven't had many other treatments.
This trial tests whether a drug called tislelizumab, given after surgery, can help prevent lung cancer from coming back. It is for people with stage I non-small cell lung cancer who have certain high-risk features and a protein called PD-L1 on their tumor cells.
Hear when a new MSI-H/dMMR Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.